Topical Tobramycin via Nasal Nebulization: New Clinical Test Demonstrates Low Serum Absorption

Serum peak & trough levels were drawn after four days of inhalation therapy at the 12th dose and revealed an average peak of 0.3 mcg /ml and an average trough of less than 0.1 mcg/ml. (In IV cases tobramycin levels would be managed to below 2.0 mcg /ml.) Ninety percent of patients reported being "better" after completing their course of therapy. No patients reported adverse side effects such as dizziness or tinnitus. Conclusion: These results further support the use of topical tobramycin as a safe method of medication administration via nasal nebulization for pseudomonas sinus infections.

I speak to sinus patients almost everyday that say this is the only therapy that has ever worked for them

Camarillo, CA (PRWEB) March 3, 2008 -- ASL Pharmacy has responded to doctor's questions regarding serum absorption of aerosolized medication: specifically inhaled Tobramycin Sulfate administered for treatment of pseudomonas sinus infections, and has completed testing conducted by an independent ENT surgeon at The Cleveland Clinic in Naples, FL. Patients were treated between July and August 2007. Please see below for more details. The complete poster may be viewed at COSM in Orlando, FL, May 1-4, 2008.

ASL Tobramycin Formula

Demographics: Patients N = 17, Age range = 27-71, Average age = 55, Women = 6, Men = 11. All patients met CT and CX criteria for Chronic Rhinosinusitis (CRS). All patients had experienced prior FESS one or more times.

Medication Dose: ASL compounded tobramycin formula 125 mg/2ml aerosolized to a particle size of 3.0-3.5 microns (pH = 6.6) and did not contain a surfactant additive. Treatment time ranged between 3 and 4.5 minutes allowing time for mid-day dosing.

Laboratory: Serum peak & trough levels were drawn after four days of therapy at the 12th dose. Trough levels were drawn 30 minutes prior to administration and peak levels were drawn 60 minutes after administration.

Results: Average peak 0.3 mcg /ml. Average trough less than 0.1 mcg/ml. (In IV cases tobramycin levels would be managed to below 2.0 mcg /ml.) Ninety percent of patients reported being "better" after completing their course of therapy. No patients reported adverse side effects such as dizziness or tinnitus.

Conclusion: These results further support the use of topical tobramycin as a safe method of medication administration via nasal nebulization.

ASL is a privately held specialty pharmacy that dispenses topical therapies for the sinuses and is currently dispensing tobramycin to patients nationwide on doctors' order. ASL's compounded tobramycin is covered under medical insurance plans, which in most cases results in low patient co-payments with limited financial responsibility.

"I speak to sinus patients almost everyday that say this is the only therapy that has ever worked for them," says Cal Tarrant, CMO for Aerosol Sciencs Labs.

Please call their office @ 866-552-7579 for more details, to request a copy of these results, or to discuss a patient case with one of their pharmacists. Customers may also visit the website at www.aslrx.com to review their list of readily available medications. They look forward to serving both doctors and patients with CRS.

Click here to receive a free physician starter pack.

###

Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/TG92ZS1UaGlyLVBpZ2ctQ291cC1Ib3JyLVplcm8=

tobramycin pseudomonas sinus inhalation nasal flu cold sinus infection biofilm topical

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web

• Prominent Physician Achieves Success Using Topical Sinus Medications via Pulsitile Irrigation 2008-07-31
• Micronized Itraconazole: Another Topical Choice for Fungal Sinus Infections 2008-05-26
• Biofilms: Recent Study Supports Elimination of Biofilm Colonies; Sinus Patients may Benefit 2008-02-01
• Sinus MRSA: What to do when Methicillin Resistant Staph Aureus Infects Your Patient 2007-11-27
• 'Sinus Science Pharmacy' Observes Positive Patient Outcomes when Patients Inhale Corticosteroids and Amphotericin B 2007-10-17